ISRCTN11348079 https://doi.org/10.1186/ISRCTN11348079

Lugol's Iodine in surgical management of epithelial dysplasia in the oral cavity and oropharynx

Submission date 10/11/2015	**Recruitment status** No longer recruiting	[_] Prospectively registered [X] Protocol
Registration date 01/04/2016	**Overall study status** Completed	[_] Statistical analysis plan [_] Results
Last Edited 09/08/2022	**Condition category** Cancer	[_] Individual participant data [_] Record updated in last year

Plain English summary of protocol
https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-lugols-iodine-during-surgery-to-remove-abnormal-cells-from-the-mouth-lister

Contact information

Type(s)
Scientific

Contact name
Prof Jim McCaul

Contact details
Queen Elizabeth University Hospital
1345 Govan Road
Glasgow
United Kingdom
G51 4TF
+44 (0)141 201 1100
jmccaul@nhs.net

Type(s)
Public

Contact name
Miss Jacqueline Quantrill

Contact details
Bradford Institute for Health Research
Temple Bank House

Bradford Royal Infirmary
Duckworth Lane
Bradford
United Kingdom
BD9 6RJ
+44 1274 383921
jacqueline.quantrill@bthft.nhs.uk

Additional identifiers

Protocol serial number
McCaul 01/2014

Study information

Scientific Title
A multi-centre, randomised controlled trial assessing the effectiveness of Lugol's Iodine in Surgical managemenT of Epithelial dysplasia in the oRal cavity and oropharynx

Acronym
LISTER

Study objectives
Does intraoperative visualisation of dysplastic mucosa with Lugol’s Iodine assist in improving accuracy of excision of epithelial dysplasia of oral cavity and oropharynx?

Ethics approval required
Old ethics approval format

Ethics approval(s)
London-Harrow Research Ethics Committee, 13/10/2016, ref: 16/LO/0857

Study design
Prospective multicentre phase III randomised controlled clinical trial

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Epithelial dysplasia in the oral cavity and oropharynx

Interventions
1. Standard Treatment Group: Surgical excision of epithelial dysplasia as per usual practice
2. Intervention Treatment Group: Surgical excision of epithelial dysplasia assisted by visualisation with Lugol’s iodine

Intervention Type

Procedure/Surgery

Primary outcome(s)
Rates of surface dysplasia or carcinoma-in-situ at surface mucosal margins

Key secondary outcome(s))
1. Two-year incidence of histologically confirmed transformation to SCC in the oral/cavity /oropharynx
2. Occult SCC diagnosed histopathologically in excised mucosa
3. Surface area of mucosa excised
4. Extent of margin clearance in mm
5. Surgeon decision to re-excise at the same site following positive margins
6. Estimate of the two year recurrence rates of oral dysplasia
7. Acceptability of the technique to surgeons (intervention treatment group)
8. Safety of the technique (intervention treatment group)
9. Assessment of Quality of Life changes

Completion date
01/06/2019

Eligibility

Key inclusion criteria
1. Provision of written informed consent
2. Age≥ 18 years old
3. Epithelial dysplasia of the oral cavity or oropharynx, undergoing primary surgical excision under general anaesthesia

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Lower age limit
18 years

Sex
All

Key exclusion criteria
1. Previous surgery or radiotherapy for head and neck cancer
2. Allergy to iodine
3. Previous diagnosis of head & Neck SCC in the past 5 years or active malignancy within 2 years of randomisation (except basal cell carcinoma or carcinoma of the cervix in-situ)

Date of first enrolment

01/12/2015

Date of final enrolment
01/12/2018

Locations

Countries of recruitment
United Kingdom

England

Scotland

Study participating centre
London North West Healthcare Trust
Northwick Park Hospital
United Kingdom
HA1 3UJ

Study participating centre
Bradford Royal Infirmary
Duckworth Lane
Bradford
United Kingdom
BD9 6RJ

Study participating centre
North Manchester General Hospital
The Pennine Acute Hospitals NHS Trust
D Block Square, Level 4
Delaunays Road, Crumpsall
Manchester
United Kingdom
M8 5RB

Study participating centre
Ninewells Hospital and Dundee University Medicals
Dundee
United Kingdom
DD1 9SY

Study participating centre
Queen Elizabeth Hospital
1345 Govan Road
Glasgow
United Kingdom
G51 4TF

Sponsor information

Organisation
NHS Greater Glasgow and Clyde

ROR
https://ror.org/05kdz4d87

Funder(s)

Funder type
Charity

Funder Name
Oracle Cancer Trust

Results and Publications

Individual participant data (IPD) sharing plan
Not provided at time of registration

IPD sharing plan summary
Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No
Participant information sheet	Participant information sheet version 1.2	11/11/2025	11/11/2025	No	Yes
Protocol file		27/02/2017	09/08/2022	No	No